ReviewNano letters2026
Dual-Stimuli Injectable Platforms for Localized Breast Cancer Therapy.
Review in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locoregional breast cancer recurrence remains a significant therapeutic challenge, largely driven by limited drug selectivity and toxicity to surrounding healthy tissues. This Mini-Review examines the emerging potential of pH- and temperature-responsive formulations as injectable drug delivery systems designed to achieve preferential targeting of malignant cells. A range of advanced platforms─from smart hydrogels to hybrid constructs such as pH-sensitive liposomes embedded within thermoresponsive hydrogel matrices─are discussed, with emphasis on key design principles and synthesis strategies enabling environmental responsiveness. Among the technologies reviewed, liposome-in-hydrogel hybrid systems─still largely unexplored in breast cancer therapy─stand out for their capacity to enhance encapsulation of lipophilic therapeutics, improve formulation stability, streamline manufacturing, and provide sustained, spatially controlled drug release. Finally, critical physicochemical, mechanical, and biological characterization studies that are needed to rigorously evaluate the translational and clinical potential of these materials for the treatment of locoregional recurrent breast cancer are outlined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.